Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
CASE REPORTS
Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases
Gerhard J. MolderingsMartin RaithelFelix KratzMarc AzemarBritta HaenischSabrina HarzerJürgen Homann
Author information
JOURNALS OPEN ACCESS

2011 Volume 50 Issue 6 Pages 611-615

Details
Abstract

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.

Information related to the author
© 2011 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top